MD Anderson buys tech from Bellicum; Tarsus’ Lyme disease trial data; Rigel takes Gavreto

Plus, Ocular Therapeutix’s private placement, LimmaTech Biologics’ shigellosis vaccine data and a collaboration between Hox Therapeutics and Vernalis.

MD Anderson buys tech from Bellicum: The Texas cancer research institution said it has acquired “certain assets” and IP from its Houston neighbor, which last year started a strategic review process. MD Anderson will use the “safety switch” tech in its cell therapies, and the cancer center plans to ink non-exclusive licenses with other academic groups and biopharma companies so they can access it, as well. — Kyle LaHucik

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。